Published on
June 24, 2022
- 16:29 GMT
Transdermal Specialties Global (TSG) Completes a Phase 3 Clinical Trial of the Trans-Insulin™ Transdermal Patch
TSG's U-Strip™ Has Successfully Achieved in Type-2 Diabetics the FDA Standard of 70% of the time, maintaining the Glucose Range Between 70 and 180 mg/dl, CLAYMONT, DE, UNITED STATES, June 24, 2022 /EINPresswire.com/ -- Transdermal Specialties …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
